GlaxoSmithKline Czech Republic made a net profit of CZK 125 mil in 2015, up 42.1% when compared to the previous year. Historically, company's net profit reached an all time high of CZK 240 mil in 2011 and an all time low of CZK -7.67 mil in 2006.
This implies return on equity of 9.44% and return on invested capital of 11.2% in 2015. That is compared to 11.4% and 9.48% average seen in the last five years.
Since 2010, net profit of the firm increased by -2.13% or -0.430% a year on average.
As far as GlaxoSmithKline Czech Republic's peers are concerned, Roche Czech Republic generated ROE of 4.40% and ROCE of 2.65% in 2015, Bayer Czech Republic's profitability reached 50.6% and 29.0%, respectively. Amgen Czech Republic operated with 18.4% and 36.6% returns in 2015..